Impact of rituximab treatment on 90Y-ibritumomab dosimetry for patients with non-Hodgkin lymphoma

Journal of Nuclear Medicine

Volumn 51, Issue 1, 2010, Pages 150-157

  Shen, Sui ^a   Forero, Andres ^b   Meredith, Ruby F ^a   Shah, Jatin J ^c   Knox, Susan J ^d   Wiseman, Gregory A ^e   Usrey, Marc E ^b   LoBuglio, Albert F ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^e MAYO CLINIC   (United States)

Author keywords

90Y ibritumomab; Dosimetry; Monoclonal antibodies; Radiobiology dosimetry; Radionuclide therapy; Rituximab; Zevalin

Indexed keywords

FLUDARABINE; IBRITUMOMAB TIUXETAN; MITOMYCIN C; NITROSOUREA; RITUXIMAB;

ARTICLE; B CELL LYMPHOMA; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DOSIMETRY; DRUG ACTIVITY; HUMAN; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE DISTRIBUTION;

ALGORITHMS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; INDIUM RADIOISOTOPES; ISOTOPE LABELING; LYMPHOMA, NON-HODGKIN; ORGAN SIZE; POSITRON-EMISSION TOMOGRAPHY; RADIOMETRY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED; YTTRIUM RADIOISOTOPES;

EID: 75149131678     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.066597     Document Type: Article

References (37)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. CA Cancer J Clin. 1996;46:5-27.
2. Gallagher CJ, Gregory WM, Jones AE, et al. Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol. 1986;4:1470-1480.
3. Foon K, Fisher R. Lymphomas. In: Beutler E, Lichtman M, Coller B, et al., eds. Williams Hematology. 5th ed. New York, NY: McGraw-Hill, Inc.; 1993.
4. Stashenko P, Nadler LM, Hardy R, Schlossman SF. Characterization of a human B lymphocyte-specific antigen. J Immunol. 1980;125:1678-1685.
5. Gordon LI, Molina A, Witzig T, et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD201 B-cell lymphoma: long-term followup of a phase 1/2 study. Blood. 2004;103:4429-4431.
6. Zevalin: Full Prescribing Information. Available at: http://www.zevalin. com/pdf/Zevalin-PI-website.pdf. Accessed November 2009.
7. Forero A, LoBuglio AF. History of antibody therapy for non-Hodgkin's lymphoma. Semin Oncol. 2003;30:1-5.
8. Shah J, Wang W, Harrough VD, et al. Retreatment with yttrium-90 ibritumomab tiuxetan in patients with B-cell non-Hodgkin's lymphoma. Leuk Lymphoma. 2007;48:1736-1744.
9. Shen S, Forero A, LoBuglio AF, et al. Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies. J Nucl Med. 2005;46:642-651.
10. Fisher DR, Shen S, Meredith RF. MIRD dose estimate report no. 20: radiation absorbed-dose estimates for 111In- and 90Y-ibritumomab tiuxetan. J Nucl Med. 2009;50:644-652.
11. DeNardo GL, DeNardo SJ, Macey DJ, Mills SL. Quantitative pharmacokinetics of radiolabeled monoclonal antibodies for imaging and therapy in patients. In: Srivastava SC, ed. Radiolabeled Monoclonal Antibodies for Imaging and Therapy. New York, NY: Plenum; 1988:293-310.
12. Macey DJ, DeNardo GL, DeNardo SJ. A treatment planning program for radioimmunotherapy. In: Vaeth JM, Meyer JL, eds. The Present and Future Role of Monoclonal Antibodies in the Management of Cancer: Frontiers of Radiation Therapy and Oncology. San Francisco: CA: Basel, Karger; 1990: 123-131.
13. Thomas SR, Maxon HR, Kereiakes JG. In vivo quantitation of lesion radioactivity using external counting methods. Med Phys. 1976;03:253-255.
14. Siegel JA, Thomas SR, Stubbs JB, et al. MIRD pamphlet no. 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med. 1999;40(suppl): 37S-61S.
15. Hammond ND, Moldofsky PJ, Beardsley MR, Mulhern CB Jr. External imaging techniques for quantitation of distribution of I-131 F(ab')2 fragments of monoclonal antibody in humans. Med Phys. 1984;11:778-783.
16. Shen S, DeNardo GL, DeNardo SJ. Quantitative bremsstrahlung imaging of yttrium-90 using a Wiener filter. Med Phys. 1994;21:1409-1417.
17. International Commission on Radiological Protection (ICRP). Basic Anatomical and Physiological Data for Use in Radiological Protection: Reference Values. ICRP publication 23. New York, NY: International Commission on Radiological Protection; 1987.
18. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825-2833.
19. Silverman S, DeNardo GL, Siegel E. Determination of spleen size by scintigraphy. Cancer Biother Radiopharm. 1999;14:407-411.
20. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023-1027.
21. Thomas SR, Stabin MG, Chen CT, Samaratunga RC. MIRD pamphlet no. 14: a dynamic urinary bladder model for radiation dose calculations. J Nucl Med. 1992;33:783-802.
22. Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 1996;37:538-546.
23. Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med. 1993;34:689-694.
24. Shen S, DeNardo GL, Sgouros G, O'Donnell RT, DeNardo SJ. Practical determination of patient-specific marrow dose using radioactivity concentration in blood and body. J Nucl Med. 1999;40:2102-2106.
25. Siegel JA, Stabin MG. Absorbed fractions for electrons and beta particles in spheres of various sizes. J Nucl Med. 1994;35:152-156.
26. Dawson B, Trapp RG. Basic & Clinical Biostatistics. 4th ed. New York, NY: Lange Medical Books/McGraw-Hill; 2004.
27. Illidge TM, Bayne M, Brown NS, et al. Phase 1/2 study of fractionated 131Irituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. Blood. 2009;113: 1412-1421.
28. 131I Lym-1 monoclonal antibodies. Int J Cancer Suppl. 1988;3:96-101.
29. Meredith RF, Bueschen AJ, Khazaeli MB, et al. Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49. J Nucl Med. 1994;35: 1017-1022.
30. 131I-labeled monoclonal antibody therapy with interferon in patients with metastatic colorectal cancer. Clin Cancer Res. 1996;2:1811-1818.
31. DeNardo SJ, O'Grady LF, Richman CM, et al. Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody. Anticancer Res. 1997;17: 1745-1751.
32. DeNardo SJ, Richman CM, Goldstein DS, et al. Yttrium-90/indium-111- DOTApeptide-chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer. Anticancer Res. 1997;17:1735-1744.
33. 90Y-2IT-BADLym-1 in patients with non-Hodgkin's lymphoma. Anticancer Res. 2000;20: 3647-3655.
34. DeNardo GL, O'Donnell RT, Shen S, et al. Radiation dosimetry for 90Y-2IT-BAD-Lym-1 extrapolated from pharmacokinetics using 111In-2IT-BADLym-1 in patients with non-Hodgkin's lymphoma. J Nucl Med. 2000;41: 952-958.
35. 90Y-CC49 monoclonal antibody therapy in patients with advanced non-small cell lung cancer: effect of chelating agents and paclitaxel co-administration. Cancer Biother Radiopharm. 2005;20:467-478.
36. Meredith R, Shen S, Macey D, et al. Comparison of biodistribution, dosimetry, and outcome from clinical trials of radionuclide-CC49 antibody therapy. Cancer Biother Radiopharm. 2003;18:393-404.
37. 90Y-ibritumomab tiuxetan: comparative dosimetric study for tailored treatment. J Nucl Med. 2007;48:1871-1879.